Lee M. Krug, MD

April 1, 2016

|

By

|

Estimated Read Time:

1–2 minutes

Lee M. Krug has taken a position as the Immuno-Oncology Disease Area Head for Lung and Head & Neck Cancers in US Medical at Bristol-Myers Squibb. He assumes this role following 15 years on the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center where he focused his clinical research primarily in small-cell lung cancer and mesothelioma.

About the Authors

Share this Article:

Lee M. Krug, MD

Recent Posts

IASLC Launches Beta Version of VIKTOR

Patient Charts: How to Carefully Manage Patient Access to Health Information

CAN-2409 Plus Valacyclovir Extends Survival in ICI-Refractory NSCLC

Using Early ctDNA, Study Findings Inform Prognostic Model

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care